MEDIWOUND LTD (MDWD)

IL0011316309 - Common Stock

16.98  -0.31 (-1.79%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

MEDIWOUND LTD

NASDAQ:MDWD (5/17/2024, 7:12:34 PM)

16.98

-0.31 (-1.79%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap161.14M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

MDWD Daily chart

Company Profile

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

Company Info

MEDIWOUND LTD

42 Hayarkon Street

YAVNE 8122745

P: 97289324010

CEO: Sharon Malka

Employees: 73

Website: https://www.mediwound.com/

MDWD News

News Image24 days ago - MediWound Ltd.MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
News Image24 days ago - MediWound Ltd.MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong correlation between wound bed...

News Image2 months ago - InvestorPlaceMDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023

MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

News Image2 months ago - BusinessInsiderMDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips MediWound (NASDAQ:MDWD) just reported results for the fourth quarter of 2023.Me...

News Image2 months ago - MediWound Ltd.MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
News Image2 months ago - MediWound Ltd.MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

$19 million revenue in 2023; $24 million projected revenue in 2024NexoBrid® commercially launched in U.S., Japan, IndiaPotential blockbuster EscharEx® to...

MDWD Twits

Here you can normally see the latest stock twits on MDWD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example